Abstract: There is disclosed a platinum ion chelating dipyridoxyl compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein the dipyridoxyl compound is uncoordinated or coordinated with a metal ion which is not a transition metal, for prevention or treatment of chemotherapy drug induced peripheral sensory neuropathy in a patient, wherein the chemotherapy drug comprises platinum ions. An example of such a chemotherapy drug is oxaliplatin. The drawbacks of previous metal complexed compounds containing manganese ions are eliminated. A more frequent use of the drug is possible since the problem in the prior art with accumulated manganese neurotoxicity is eliminated. The compounds can be administered both temporally and spatially separately from chemotherapy.

Abstract: There is disclosed a platinum ion chelating dipyridoxyl compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein the dipyridoxyl compound is uncoordinated or coordinated with a metal ion which is not a transition metal, for prevention or treatment of chemotherapy drug induced peripheral sensory neuropathy in a patient, wherein the chemotherapy drug comprises platinum ions. An example of such a chemotherapy drug is oxaliplatin. The drawbacks of previous metal complexed compounds containing manganese ions are eliminated. A more frequent use of the drug is possible since the problem in the prior art with accumulated manganese neurotoxicity is eliminated. The compounds can be administered both temporally and spatially separately from chemotherapy.

Abstract: Pharmaceutical compositions comprise a first compound of Formula I or a physiologically acceptable salt thereof, and a cyto-protective amount of a manganese chelate of N,N?-dipyridoxyl ethylenediamine-N,N?-diacetic acid (MnPLED): wherein R1, R2, R3, R4 and X are defined in the specification.

Abstract: Compound of Formula I or a salt thereof for treating cancer, wherein X represents CH or N; R1 represents hydrogen or —CH2COR5; R5 represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido; R2 represents ZYR6; Z represents a bond, or a C1-3 alkylene or oxoalkylene group optionally substituted by R7; Y represents a bond, an oxygen atom or NR6; R6 is a hydrogen atom, COOR8, an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more selected from COOR8, CONR82, NR82, OR8, ?NR8, ?O, OP(O)(OR8)R7 and OSO3M; R7 is hydroxy, an optionally hydroxylated, optionally alkoxylated alkyl or aminoalkyl group; R8 is a hydrogen atom or an optionally hydroxylated, optionally alkoxylated alkyl group; M is a hydrogen atom or one equivalent of a physiologically tolerable cation; R3 represents C1-8 alkylene, 1,2-cykloalkylene, or 1,2-arylene, optionally substituted with R7; and R4 represents hydrogen or C1-3 alkyl.

Abstract: Compound of Formula I or a salt thereof for treating cancer, wherein X represents CH or N; R1 represents hydrogen or —CH2COR5; R5 represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido; R2 represents ZYR6; Z represents a bond, or a C1-3 alkylene or oxoalkylene group optionally substituted by R7; Y represents a bond, an oxygen atom or NR6; R6 is a hydrogen atom, COOR8, an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more selected from COOR8, CONR82, NR82, OR8, ?NR8, ?O, OP(O)(OR8)R7 and OSO3M; R7 is hydroxy, an optionally hydroxylated, optionally alkoxylated alkyl or aminoalkyl group; R8 is a hydrogen atom or an optionally hydroxylated, optionally alkoxylated alkyl group; M is a hydrogen atom or one equivalent of a physiologically tolerable cation; R3 represents C1-8 alkylene, 1,2-cykloalkylene, or 1,2-arylene, optionally substituted with R7; and R4 represents hydrogen or C1-3 alkyl.